Whitehawk Therapeutics (NASDAQ:WHWK) Raised to Hold at Wall Street Zen

Whitehawk Therapeutics (NASDAQ:WHWK) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Citizens Jmp began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 price target for the company. Citigroup began coverage on Whitehawk Therapeutics in a report on Thursday, April 16th. They issued an “outperform” rating on the stock. B. Riley Financial started coverage on Whitehawk Therapeutics in a research report on Thursday, June 25th. They issued a “buy” rating and a $10.00 price target for the company. Finally, Leerink Partners initiated coverage on shares of Whitehawk Therapeutics in a research note on Monday, July 13th. They set an “outperform” rating and a $9.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.20.

Whitehawk Therapeutics Price Performance

WHWK stock opened at $4.76 on Friday. Whitehawk Therapeutics has a twelve month low of $1.57 and a twelve month high of $5.49. The firm has a market cap of $235.39 million, a price-to-earnings ratio of -4.25 and a beta of 0.76. The business’s fifty day simple moving average is $4.11 and its two-hundred day simple moving average is $3.79.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. Research analysts expect that Whitehawk Therapeutics will post -1.37 EPS for the current year.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in WHWK. BlackRock Inc. purchased a new position in shares of Whitehawk Therapeutics during the second quarter worth approximately $8,807,000. Deutsche Bank AG acquired a new stake in Whitehawk Therapeutics during the 2nd quarter worth $145,000. Bank of New York Mellon Corp purchased a new position in Whitehawk Therapeutics during the 2nd quarter worth $378,000. Seven Fleet Capital Management LP purchased a new position in Whitehawk Therapeutics during the 1st quarter worth $187,000. Finally, Bank of America Corp DE increased its stake in Whitehawk Therapeutics by 12,761.6% in the first quarter. Bank of America Corp DE now owns 52,861 shares of the company’s stock valued at $182,000 after purchasing an additional 52,450 shares during the period. Hedge funds and other institutional investors own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.